top of page
27.png

LucenceINSIGHT™

LucenceINSIGHT™ is a multi-cancer early detection test that, from a single standard blood draw, focuses on the cancers most likely to matter for you.

$495 · LucenceINSIGHT™ Core

· May be HSA/FSA eligible.
 

Test is prescription-only and must be ordered by a healthcare provider. 

​Request the test via an independent telemedicine healthcare provider.

早期癌症篩檢守護健康

及早檢測到癌症（第一期、第二期）能提高 5 年生存率。[1]

  • Liver

  • Pancreatic

  • Lung

  • Colorectal

  • Breast

  • Thyroid

及早檢測到癌症（第一期、第二期）能提高 5 年生存率。[1]

Start with LucenceINSIGHT™ Core. Make it yours.

Your family history is unique, so your screening should be too. When you request your test, you can refine it based on your family history:

  • add up to 3 additional cancers most relevant to you (LucenceINSIGHT™ Me) OR

  • choose the broadest panel across 12 cancers (LucenceINSIGHT™ 12).

6

cancers

6 essential cancers. Your starting point.

LucenceINSIGHT™ Core

9

cancers

LucenceINSIGHT™ Core plus your chosen 3 cancers.

LucenceINSIGHT™ Me

12

cancers

Comprehensive 12-cancer screening, tailored by gender.

LucenceINSIGHT™ 12

路勝因思康 Core

Comprehensive Screening.png

檢測6種關鍵癌症，佔全球癌症死亡率>50% [5]。

lucenceinsight (US -landing)_ordering.png

Ordering Workflow

1. Request online

Submit a request for the test online.

2. Physician review

A licensed physician reviews your request and, if appropriate, places the order (prescription required).

3. Kit delivery

We’ll ship the test kit to you, along with a link to schedule your mobile blood draw.

4. At-home blood collection

A phlebotomist will collect your blood sample in the comfort of your home.

5. Results & next steps

We’ll process your sample, and your physician will reach out to discuss your results and any next steps, if needed.

lucenceinsight (US)_pricing.png

Pricing

$495

LucenceINSIGHT™ Core list price​

  • Fully refundable if deemed ineligible by a physician.
     

  • May be HSA/FSA eligible.
     

  • Pay in up to 20 installments via Klarna, subject to the terms of their payment plans.
     

  • Higher-coverage panels (LucenceINSIGHT™ Me, LucenceINSIGHT™ 12) available at higher list prices.

參考：

  1. Cancer Stat Facts. NIH NCI SEER. 訪問日期：July 28, 2025. https://seer.cancer.gov/statfacts/.

  2. Bray, F. et al. CA Cancer J. Clin. 2024; 74(3): 229-263.基於結直腸癌、子宮頸癌及乳腺癌數據計算得出。

  3. 在新加坡和香港，公共機構僅建議進行結直腸癌、子宮頸癌及乳腺癌的篩檢。(HealthHub. Screen for Life. Singapore Ministry of Health. https://www.healthhub.sg/programmes/healthiersgscreening/screening-faq#home. 訪問日期： September 15 2025; Hong Kong Cancer Registry. Prevention and screening. https://www.cancer.gov.hk/en/hong_kong_cancer/prevention_and_screening.html#3. 訪問日期： September 15, 2025.)

  4. Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.

  5. Cancer Stat Facts. NIH NCI SEER. 訪問日期： July 28, 2025. https://seer.cancer.gov/statfacts/. 癌症死亡率涵蓋率表示：LucenceINSIGHT Core涵蓋的6種癌症類型、LucenceINSIGHT 12涵蓋的12種癌症類型，以及LucenceINSIGHT 50涵蓋的50種癌症類型，共同佔據全球癌症死亡總數的該比例。總數不包含其他指定癌症及未指定部位的癌症死亡案例，其計算方式為各癌症類型全球死亡率的上限值，數據源自GLOBOCAN 2022資料庫。癌症部位依據最接近的現有男女通用死亡率數據，對應至GLOBOCAN分類。所有源自GLOBOCAN數據的百分比均屬保守估計。 訪問日期： November 17, 2025 (https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf and https://gco.iarc.who.int/media/globocan/material/GLOBOCAN2022_annexes.pdf)

  6. Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042. 基於 ctDNA 的路勝因思康™ 檢測顯示，其特異性為 99.0%（310/313 名自稱健康捐贈者），整體靈敏度為 80.9%（233/288 名癌症患者）。在分析的 21 類原發組織中，62.4% 的病例（平均值 73.6%，範圍26.7% - 100%）可作出高置信度預測，整體準確度達 87.7%（平均值 84.9%，範圍 33.3% - 100%）

  7. Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.

  8. Stejskal P, et al. Mol Cancer 2023; 22(15).

Get in Touch

Dropdown
測試名稱
bottom of page